Αρχική World News Genetic Cancer Screenings in Younger Women May Be Cost-Effective and Lead to...

Genetic Cancer Screenings in Younger Women May Be Cost-Effective and Lead to Fewer Cases

Many women may wonder if they have genetic mutations that make them more apt to develop breast and ovarian cancers. Is it worth it for women to be tested and see if they may be carrying those mutations? A new study says it just might be, for those who are younger.

Woman at doctor
PHOTO: ADOBE STOCK/HERO IMAGES

According to a study published in JAMA Network Open, population-wide testing for genetic mutations connected with hereditary breast and ovarian cancers may be cost effective and have health benefits for women between 20 and 35. However, older women didn’t see the same benefits because most preventative surgeries happen before the age of 50 and most genetic cancer cases are diagnosed after age 50. Older women don’t have as much time to act.

The findings come from research done by the RISE Consortium, which works to determine the long-term health and economic benefit to genetic screening. Researchers developed a model to compare population screening for hereditary breast and ovarian cancers in an unselected population of women who had no prior diagnosis versus no screening. BRCA1 and BRCA2 were among the harmful mutations included.

Fewer Cancer Cases and Increased Quality of Life

The study found that population screening of 30-year-old women led to 75 fewer cancer cases per 100 thousand women. Among 45-year-olds, it wasn’t quite as effective, with only 24 fewer cases per 100 thousand women. Researchers also looked at quality-adjusted-life-years, or QALYs. They found that 30-year-old women gained 288 QALYs, while 45-year-old women only gained 97.

Woman getting mammogram
PHOTO: ADOBE STOCK/HERO IMAGES

Dr. Josh Peterson, one of the study authors and a principal investigator for RISE, says, “Screening for genetic conditions and risks has become common for the perinatal period, but whether to do so for adults is still debated. This study adds to the growing literature that testing for common genetic risks, such as hereditary breast and ovarian cancer, early in adult life is beneficial to patients and cost-effective from a societal perspective.”

The study authors noted that more research is needed to see if women who test negative still get recommended health screenings for all women.

Certain Genetic Mutations Greatly Increase Cancer Risk

According to the National Cancer Institute, 55%-72% of women who inherit a harmful BRCA1 mutation will develop breast cancer by the age of 70-80, while 45%-69% of those with a harmful BRCA2 mutation will. For ovarian cancer, those who have inherited the BRCA1 mutation have a 39-44% chance of developing the disease by age 70-80, and those with the BRCA2 mutation have an 11-17% chance.

Article continues below

Our Featured Programs

See how we’re making a difference for People, Pets, and the Planet and how you can get involved!

On an individual level, the United States Preventive Services Task Force recommends that women whose family members have these cancers be evaluated themselves to see if their family history may be associated with mutations. If it is, it may be helpful for the family member with the cancer to be tested first. Depending on those results, other family members may choose genetic counseling or to be tested.

Woman in laboratory
PHOTO: PIXABAY/JARMOLUK

Michelle has a broadcasting background, loves to write, and enjoys a good baseball game. You may find her on a hiking trail.

Provide Mammograms

Support those fighting Breast Cancer at The Breast Cancer Site for free!

Whizzco Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Making Important Decisions During Cancer: A Survivor’s Story

Bethany Hart lives with her husband Kevin, sons, and 3 dogs in the suburbs of Indianapolis, Indiana. She is a survivor of small cell neuroendocrine cervical cancer....

Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer

October 26, 2021, by NCI Staff Atezolizumab (Tecentriq) is approved as an additional treatment for some patients with stage II to IIIA (pictured) non-small cell...

Cure Probability Models for Evaluation of Patients with a Previous Cancer Diagnosis for Solid Organ Transplantation

Findings from a first study that applied a formal statistical framework to inform the evaluation of transplant candidates with a previous cancer diagnosis were...

Teacher Reads To Students One Day After Having Brain Surgery

Meucci - who had her surgery on a Wednesday - was going live from her intensive care unit hospital room that very next Thursday...

6 things you need to know about cervical screening

This article was originally published in 2017 during Cervical Screening Awareness Week. It has now been reviewed and updated. Cervical screening, also known as the...

EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan

On 14 October 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...